Philip Ramsden
YOU?
Author Swipe
View article: Figure S12 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S12 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Inhibition or knockdown of CDK4/6 sensitizes CCNE1-high, CDKN2A knockout cells to BLU-222.
View article: Figure S14 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S14 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
BLU-222 + ribociclib PK and body weight measurements in OVK18, MFE-296, OVCAR-3 T2A xenograft studies.
View article: Figure S15 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S15 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Additional BLU-222 and chemotherapy combination studies in mice in vivo.
View article: Figure S5 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S5 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
BLU-222 induced cell cycle phase changes in CCNE1 copy number normal, mRNA-high cell lines.
View article: Figure S2 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S2 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
CDK2-depletion induces antiproliferative effect in CCNE1-amplified cell lines.
View article: Figure S5 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S5 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
BLU-222 induced cell cycle phase changes in CCNE1 copy number normal, mRNA-high cell lines.
View article: Figure S6 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S6 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Evaluating Rb and p16 as markers of response to BLU-222 in CCNE1-high cell lines
View article: Figure S4 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S4 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Cell cycle profiling in CCNE1-amplified and CCNE1-normal cell lines treated with BLU-222 for 24h.
View article: Figure S10 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S10 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Endometrial PDX model biomarker expression, PK/PD, and body weight measurements.
View article: Figure S14 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S14 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
BLU-222 + ribociclib PK and body weight measurements in OVK18, MFE-296, OVCAR-3 T2A xenograft studies.
View article: Figure S9 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S9 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Evaluating ploidy and ubiquitin-related pathways in BLU-222 responders versus non-responders.
View article: Supplementary Tables from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Supplementary Tables from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Supplemental Tables
View article: Data from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Data from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
BLU-222 is an investigational, potent, highly selective, orally bioavailable cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development. BLU-222 demonstrated robust antitumor activity in select CCNE1-high ovarian and endometrial ca…
View article: Figure S13 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S13 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
In vitro BLU-222 + ribociclib ZIP synergy plots
View article: Figure S4 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S4 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Cell cycle profiling in CCNE1-amplified and CCNE1-normal cell lines treated with BLU-222 for 24h.
View article: Figure S2 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S2 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
CDK2-depletion induces antiproliferative effect in CCNE1-amplified cell lines.
View article: Figure S11 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S11 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Evaluating CDKN2A up- or downregulation in CCNE1-high ovarian and endometrial cell lines.
View article: Supplementary Information from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Supplementary Information from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Supplementary Figure legends and methods
View article: Supplementary Information from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Supplementary Information from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Supplementary Figure legends and methods
View article: Figure S8 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S8 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
BLU-222 antiproliferative effect is mediated by CDK2-RB-E2F axis.
View article: Figure S1 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S1 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Evaluation of CDK2-dependency in cell lines using CCLE/DepMap.
View article: Figure S3 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S3 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
OVCAR-3 T2A and ES-2 BLU-222 PK and pRb PD from CDX studies.
View article: Figure S1 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S1 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Evaluation of CDK2-dependency in cell lines using CCLE/DepMap.
View article: Figure S10 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S10 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Endometrial PDX model biomarker expression, PK/PD, and body weight measurements.
View article: Figure S11 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S11 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Evaluating CDKN2A up- or downregulation in CCNE1-high ovarian and endometrial cell lines.
View article: Figure S8 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S8 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
BLU-222 antiproliferative effect is mediated by CDK2-RB-E2F axis.
View article: Figure S15 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S15 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Additional BLU-222 and chemotherapy combination studies in mice in vivo.
View article: Figure S7 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S7 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Cyclin E1, Rb, and p16 protein expression measured by Western blot in ovarian and endometrial cell lines.
View article: Figure S9 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S9 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Evaluating ploidy and ubiquitin-related pathways in BLU-222 responders versus non-responders.
View article: Figure S6 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors
Figure S6 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in <i>CCNE1</i>-Aberrant Ovarian and Endometrial Tumors Open
Evaluating Rb and p16 as markers of response to BLU-222 in CCNE1-high cell lines